S-1/A: Notable Labs Files Amendment for Share Purchase Warrant

Notable Labs, Ltd. files an amendment related to a prefunded ordinary share purchase warrant, detailing terms, definitions, and exercise conditions.

Summary

• Notable Labs, Ltd. has filed an amendment regarding a prefunded Ordinary Share purchase warrant.
• The warrant allows the holder to subscribe for and purchase Ordinary Shares from the company.
• The purchase price of one Ordinary Share under this warrant is equal to the Exercise Price, as defined in Section 2(b).
• The warrant can be exercised any time after the Initial Exercise Date until the Termination Date.
• The document defines key terms such as 'Affiliate', 'Bid Price', 'Business Day', 'Commission', 'Exchange Act', 'Ordinary Shares', 'Person', 'Securities Act', 'Subsidiary', 'Trading Day', 'Trading Market', 'Transfer Agent', and 'VWAP'.
• The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was prefunded to the Company on or prior to the Initial Exercise Date.
• The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date.
• The remaining unpaid exercise price per Warrant Share shall be $0.0001, subject to adjustment hereunder.
• The warrant includes provisions for cashless exercise, adjustments for share dividends and splits, subsequent rights offerings, pro rata distributions, and fundamental transactions.
• The Holder's exercise is limited to ensure they do not exceed a maximum percentage of beneficial ownership, which is 4.99%, 9.99%, 19.99%, or 24.99% depending on their status.
• The warrant and its rights are transferable with written assignment and funds for transfer taxes.
• The document outlines procedures for transfer, division, and combination of warrants.
• The warrant does not grant shareholder rights until exercised, and settlement will not be in cash.
• The document is governed by the laws of the State of New York, and legal proceedings will be commenced exclusively in the state and federal courts sitting in the City of New York.

Sentiment

Score: 7

Explanation: The document is a standard legal agreement, so the sentiment is neutral. The detailed terms and conditions suggest a well-structured financial instrument.

Positives

• The prefunded nature of the warrant reduces the financial risk for Notable Labs upon exercise.
• The cashless exercise option provides flexibility for the holder.
• The detailed adjustment clauses protect the holder's investment in various scenarios.
• The transferability of the warrant enhances its liquidity.

Negatives

• The Holder's exercise is limited to ensure they do not exceed a maximum percentage of beneficial ownership, which is 4.99%, 9.99%, 19.99%, or 24.99% depending on their status.
• The warrant does not grant shareholder rights until exercised.
• The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date.

Risks

• The Holder's exercise is limited to ensure they do not exceed a maximum percentage of beneficial ownership, which is 4.99%, 9.99%, 19.99%, or 24.99% depending on their status.
• The warrant does not grant shareholder rights until exercised.
• The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date.
• The document is governed by the laws of the State of New York, and legal proceedings will be commenced exclusively in the state and federal courts sitting in the City of New York.

Future Outlook

The warrant outlines potential adjustments to the exercise price and number of shares based on future events such as dividends, splits, and fundamental transactions, indicating a flexible framework for future scenarios.

Industry Context

The document reflects common financial instruments used in the biotechnology industry to raise capital and incentivize investment, with specific clauses to manage risk and compliance with securities regulations.

Comparison to Industry Standards

• The structure of the warrant, including prefunding and cashless exercise options, is consistent with practices used by companies like Cassava Sciences and Ocugen to raise capital.
• The beneficial ownership limitations are similar to those used by companies like Amyris and Biocept to prevent hostile takeovers.
• The detailed adjustment clauses for corporate actions are standard in warrants issued by companies like Sorrento Therapeutics and Vaxart.

Stakeholder Impact

• Potential dilution for existing shareholders upon exercise of the warrant.
• Increased capital for the company to fund operations.
• Potential for increased share price if the company performs well and the warrant is exercised.

Next Steps

• Holder to decide when and how to exercise the warrant.
• Company to ensure sufficient Ordinary Shares are available for issuance.
• Company to notify Holder of any adjustments to the Exercise Price or number of Warrant Shares.

Key Dates

Keywords

warrant, ordinary shares, exercise price, prefunded, holder, company, exercise, trading, shares, trading market